Cost effectiveness analysis of the surgical treatment of female urinary incontinence using slings by Montesino Semper, Manuel F. et al.
 Departamento de Economía 
 
Ekonomia Saila 
Documentos de Trabajo 
 
Lan Gaiak 
COST-EFFECTIVENESS ANALYSIS OF THE SURGICAL 
TREATMENT OF FEMALE URINARY INCONTINENCE 
USING SLINGS 
 
Manuel F. Montesino-Semper 
Jesús M. Jiménez-Calvo 
Juan M. Cabasés 
Eduardo Sánchez-Iriso 
Antonio Hualde-Alfaro 
Diego García-García 
D.T. 1303 
1 
 
 
 
 
COST-EFFECTIVENESS ANALYSIS OF THE SURGICAL TREATMENT OF 
FEMALE URINARY INCONTINENCE USING SLINGS 
 
Manuel F Montesino-Semper1, Jesús M Jiménez-Calvo1, Juan M Cabasés2, Eduardo Sánchez-
Iriso2, Antonio Hualde-Alfaro1, Diego García-García1 
 
 
 
1Urology Service. “Virgen del Camino” Hospital.  
c/ Irunlarrea, 4. 31008. Pamplona (Navarra). Spain. E-mail: mmontess@navarra.es 
2Department of Economics. Public University of Navarra.   
Campus de Arrosadía. 31006. Pamplona (Navarra). Spain 
 
 
 
ABSTRACT 
Objective. To determine the cost-utility and cost-effectiveness of the surgical treatment of 
female urinary incontinence using suburethral slings compared with therapeutic abstention. 
Study Design. An economic analysis was performed on 69 women receiving surgical treatment 
for urinary incontinence using suburethral slings. To calculate the procedure´s cost-
effectiveness, an incremental analysis up to 1 year was performed using the incremental cost-
effectiveness ratio (ICER). The costs were calculated using a cost-by-process model. Answers 
to the health-related quality of life questionnaires EQ-5D (generic) and International 
Consultation Incontinence Questionnaire Short-form (specific) were collected before the 
operation and as well as 1 month and 1 year post-operation to calculate the utility, using quality-
adjusted life years (QALY), and the effectiveness, respectively. A sensitivity analysis was 
performed by calculating the Incremental Cost-Effectiveness Ratio (ICER) at 5 years post-
operation. To complete the economic evaluation, we derived confidence ellipses and 
acceptability curves. The analysis was conducted for the entire sample and also for each type of 
urinary incontinence. 
Results. In total, 45 women presented with stress incontinence, 15 with mixed incontinence and 
9 with incontinence associated with prolapse. The average cost per patient at 1 year post-
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operation was 1,220 €. The QALY achieved at 1 year was 0.046. The results reveal an ICER at 
1 year of 26,288 €/QALY, which is below the cost-effectiveness threshold considered 
acceptable, and this value was lower for stress incontinence (21,191 €/QALY). To achieve 
greater temporal perspective, we examined the ICER at 5 years, which was 10,141 €/QALY, 
demonstrating that the programme is clearly efficient. The cost-effectiveness was 106.5 €/ 
International Consultation Incontinence Questionnaire Short-form unit. 
Conclusion. Surgery for female urinary incontinence using slings is cost-effective compared 
with abstention in our public health environment. 
 
Key Words. Female urinary incontinence. Surgical treatment. Cost-utility analysis. Cost-
effectiveness analysis. QALY. 
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INTRODUCTION 
The introduction at the end of the last century of the surgical treatment of female 
urinary incontinence (UI) by TVT-type suburethral slings, which achieves excellent results has 
stimulated cost-effectiveness studies to compare this minimally invasive technique with 
traditional procedures, including slings, colposuspension (1-7), or pharmacological treatments 
(8). 
In this study, a cost-effectiveness analysis (CEA) and a cost-utility analysis (CUA) were 
conducted for the surgical treatment of female UI using slings compared with abstention. 
 
MATERIALS AND METHODS 
1.-INCREMENTAL STUDY 
We performed an economic evaluation of surgery (compared with no surgery) by 
estimating the incremental costs of the surgical treatment of UI and its incremental 
effectiveness. The results are presented in terms of the incremental cost-effectiveness ratio 
(ICER) from the perspective of the service provider and in the frame of a public health care 
system in Navarra (Spain). Cost-effectiveness acceptability curves (CEAC) and confidence 
ellipses were also calculated. 
Cost measurement 
The costs were evaluated using the cost-by-process methodology previously described 
(9). The costs included medical consultations before surgery, urodynamic and pre-operative 
studies, hospital stays in Major Outpatient Surgery (MOS) or in a hospital ward, surgical costs 
(healthcare personnel, material including slings), and medical consultations and drugs after 
surgery, including re-interventions if required for the first year, which were individualised per 
patient. The costs outside of the programme were considered to be 0 €. Because the study 
perspective is that of the Health System provider, there was no additional cost if the patient did 
not undergo an operation. 
Utility and effectiveness measurement 
For the cost-utility analysis (CUA), we used quality-adjusted life years (QALY) as a 
utility measure, with one QALY equal to one year in full health. This measure was obtained by 
a health-related quality of life generic questionnaire (HRQL), EQ-5D (10), which provides a 
value or index (EQ-index) between 0 and 1 and uses the time trade-off (TTO) method (11). For 
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the incremental calculation of QALY one year after the surgery, we used the formula for the 
area under the curve (12, 13), assuming that patients who were not treated maintained the same 
EQ-index during the period considered (Figure 1). 
Figure 1 
QALYs gained with the intervention. 1= Area under the curve at 1 month after intervention; 1+2+3= Area 
under the curve at 1 year after intervention using monthly means 
 
 
For the CEA, we used changes in the ICIQ-SF (International Consultation Incontinence 
Questionnaire Short-form) specific questionnaire as the effectiveness measure. Its values range 
from 0 (absence of UI) to 21 (the worst possible status of UI). 
The patients were invited to complete both the EQ-5D and ICIQ-SF before the surgery 
and at 1 month and at 1 year after the surgery. 
Calculation of ICER 
The formula for the incremental calculation (ICER) is as follows: 
 
                    Cost of surgery-Cost without surgery* 
ICER=   
                  Effectiveness after surgery-Effectiveness before surgery 
(*): Null initial costs estimated. Cost in €. Effectiveness: Effectiveness in EQ-index or ICIQ-SF. 
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The reference value of 30,000 €/QALY was taken as the threshold of cost-effectiveness 
for efficiency (14). 
This method was applied to a global model including all patients and for 1 year of 
evolution using the average of the costs and effectiveness with multiple imputations (that is, in 
the case of missing data, the group average was applied). Moreover, models were developed for 
each type of incontinence: stress urinary incontinence (SUI), mixed urinary incontinence (MUI) 
and incontinence associated with pelvic organ prolapse (POP). 
Economic assessment tools 
An analysis of the ratio of the estimated cost-effectiveness was performed by 
developing confidence ellipses at 50%, 75%, and 95% and using cost-effectiveness acceptability 
curves (CEAC) as a graphical representation to quantify the uncertainty (15). For this purpose, 
we employed only the data of those patients with complete information (analysis by complete 
cases) at 1 year after the surgery. 
The models employed were the following: global (Model 1), including models with the 
value of the EQ-index (Model 1.1) and with ICIQ-SF (Model 1.2); and by the type of UI (Model 
2), including models with the value of the EQ-index and ICIQ-SF (Models 2.1 and 2.2, 
respectively). The functions are as follows: 
Model 1:  
Costsi = α0+Ti α1+u1i;  
Effectivenessi = β0+Ti β1+u2i; 
with T = 0, before surgery, and T = 1, one year after surgery; 
Model 2:  
Costsi = SUIi α01+MUIi α02+POPi α03+Ti SUIi α11+Ti MUIi α12+Ti POPi α13+u1i;  
Effectivenessi = SUIi β01+MUIi β02+POPi β03+TiSUIi β11+TiMUIi β12+Ti POPi β13+u2i  
where: 
α0a = cost before surgery;   α1a = cost after surgery 
β0a = effectiveness before surgery;  β1a = effectiveness after surgery, 
and estimated with the econometric technique known as SURE (seemingly unrelated regression 
estimator). 
 
6 
 
2.-SENSITIVITY ANALYSIS 
Because most of the costs were concentrated around the surgical intervention and the 
data for the HRQL and effectiveness remained equivalent after the first 2 years (16, 17), we 
extrapolated the calculation of the ICER 5 years with the following considerations based upon 
our data (18-20) and those of the medical literature(16, 21-24):  
1.- Outcomes: EQ-index (or ICIQ-SF as applicable) remains equal after the first year; and 
2.- Costs: patients undergo a 1-year consultation with 6% “de novo” urinary urgency requiring 
pharmacological treatment with antimuscarinic agents and 6% new interventions (re-
interventions). 
The future costs and effectiveness were discounted at an annual rate of 3%(25, 26). 
3.-Data 
We included 69 patients in this study: 45 with SUI, 15 with MUI, and 9 with 
incontinence associated with POP. All of the patients underwent a complete economic cost 
analysis. 
With respect to the response rate of the HRQL of the EQ-5D questionnaires, we had 67 
preoperative, 61 early post-operative and 67 late postoperative registers at1 year. We removed 
two patients with MUI because they developed an associated acute illness (lumbosciatica and 
exacerbation of Parkinson´s disease, respectively) that significantly affected their quality of life, 
and they were treated as outliers. 
With respect to the ICIQ-SF, all patients answered the pre-operative survey, 62 
answered the post-operative survey, and 67 answered the 1-year survey. 
We implanted 47 mini-slings (39 TVT-Secur and 8 Mini-Arc), 14 transobturator (11 
TOT and 3 TOA), 3 Prolift, 4 Prolift with associated TOT and 1 Apogee with TOT. 
Additionally, at the re-interventions, 1 Mini-Arc and 1 Remeex were implanted. 
The following procedures were used during the first year: 69 first visits and 250 
successive visits, 22 urodinamic evaluations, 57 pre-operative studies, MOS hospital stay in 69 
pre-surgical and 66 post-surgical cases, 71 anti-incontinence surgeries, 43 local anaesthesia 
treatments, 10 local anaesthesia plus sedation treatments, 22 spinal anaesthesia treatments and 4 
hospital inpatient admissions. 
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RESULTS 
1.-COSTS 
The full cost of the surgical treatment of the 69 patients was 84,145€ at the end of the 
year, with an average of 1,220 €/patient: 1,067 in SUI, 1,628 in MUI and 1,664 for POP. 
2.-COST-UTILITY AND COST-EFFECTIVENESS ANALYSIS 
The results of the incremental cost-utility analysis are shown in Tables 1 and 2. The  
ICER at 1 year was 26,288 €/QALY, which was lower than the acceptable cost-effectiveness 
threshold. Thus, the programme can be considered efficient. 
 
Table 1 
Results of the incremental cost-effectiveness ratio (ICER) of the surgical treatment for female urinary 
incontinence using sling placement, with the EQ-5D-index. (N=67)  
 Cost (€) 
QALY before 
surgery 
QALY after 
surgery 
∆ QALY (EQ-
5D) 
ICER 
(€/QALY) 
1st 
year  
1,222.42 0.7585 0.8050 0.0465 26,287.99 
5th 
year 
1,501.44 3.5781 3.7261 0.1480 10,140.93 
 
 
Table 2 presents the incremental results with the EQ-index and by the type of 
incontinence at 1 and 5 years. The SUI exhibited a better ICER at 1 year, with an incremental 
cost-effectiveness ratio that was lower than the threshold reference of 30,000 €/QALY. 
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Table 2 
ICER of the surgical treatment for female urinary incontinence using sling placement by the type of UI.  
 
SUI: stress urinary incontinence; MUI: mixed urinary incontinence; POP: urinary incontinence associated 
with pelvic organ prolapse 
 
The results of the ICER after the cost-effectiveness analysis with the ICIQ-SF are 
presented in Tables 3 and 4. The ICER with the ICIQ-SF was 106.5 €/unit. 
 
Table 3  
The ICER of the surgical treatment for female urinary incontinence using sling placement of slings, with 
the ICIQ-SF. (N=69). 
 Cost (€) Auc* before 
surgery 
Auc* after 
surgery 
∆ Auc* ICIQ-
SF 
ICER (€/specific 
unit) 
1st 
year 
1,220.22 15.101 3.646 11.455 106.52 
5th 
year 
1,492.46 80.175 26.141 54.034 27.62 
(*)Auc: area under the curve. 
 
 
 
 
 
 
Type of UI 
(n) Year Cost (€) 
QALY before 
surgery 
QALY after 
surgery 
∆ QALY 
(EQ-5D) 
ICER 
(€/QALY) 
SUI (45) 
1st 1,067.70 0.7570 0.8073 0.0504 21,191.50 
5th 1,339.93 3.5706 3.6889 0.1192 11,242.08 
MUI (13) 
1st 1,628.18 0.7186 0.7683 0.0498 32,714.02 
5th 1,900.41 3.3896 3.7020 0.3124 6,083.79 
POP (9) 
1st 1,664.60 0.8231 0.8384 0.0153 108,877.63 
5th 1,916.26 3.8826 3.9347 0.0520 36,817.79 
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Table 4  
The ICER of the surgical treatment for female urinary incontinence using sling placement of slings by 
the type of UI, with ICIQ-SF.  
SUI: stress urinary incontinence; MUI: mixed urinary incontinence; POP: urinary incontinence associated with pelvic 
organ prolapse. (*)Auc: area under the curve. 
 
3.-SENSITIVITY ANALYSIS 
With a longer temporary perspective, the ICER at 5 years was reduced to 10,141 
€/QALY (Table 1), demonstrating that the programme was clearly efficient. Similarly, at 5 
years, the ICER for each type of UI was reduced (Table 2), with the ICER of POP being the 
only one above the efficiency threshold. 
The CEA by means of the ICIQ-SF is presented in Table 3 for the global model and in 
Table 4 for each type of UI. 
4.-RESULTS WITH THE ECONOMIC ASSESSMENT TOOLS 
To help develop a more intuitive interpretation of the results, the coefficients of the 
ICIQ-SF were obtained by subtracting the real value from the maximum of 21 and dividing by 
100. 
Tables 5 and 6 present the global results (Model 1) and the results by the type of UI 
(Model 2), with respect to the costs and effectiveness. 
 
 
 
 
 
 
 
Type of UI 
(n) Cost € 
 Auc* sin 
cirugía 
Auc* 
poscirugía 
∆ Area ICIQ-
SF 
ICER 
(€/specific unit) 
SUI (45) 1,067.70 15.444 2.752 12.692 84.11 
MUI (15) 1,411.12 14.733 4.664 10.069 140.13 
POP (9) 1,664.66 14 6.57 7.430 224.03 
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Table 5  
Model 1, the basal and incremental costs and effectiveness by the type of questionnaire. 
 
 
 
 
EQ-5D (n=118) ICIQ-SF/100 (n=122) 
Coefficient (s.d.) P Coefficient (s.d.) P 
Equation 1 
Basal cost 0.000 (27.989) 1.000 0.000 (43.589) 1.000 
Incremental cost 1166.19 (39.582) 0.000 1230.51 (61.644) 0.000 
Equation 2 
Basal 
Effectiveness 
0.757 (0.021) 0.000 0.059 (0.004) 0.000 
Incremental 
Effectiveness 
0.038 (0.030) 0.211 0.115 (0.006) 0.000 
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Table 6  
Model 2, the basal and incremental costs and effectiveness by the type of questionnaire and type of UI. 
 
EQ-5D (n=118) ICIQ-SF/100 (n=122) 
Coefficient 
(s.d.)                p  
Coefficient 
(s.d.)                P 
Equation 1 
Basal cost *SUI 0.000 (25.649) 1.000 0.000 (47.225) 1.000 
Basal cost *MUI 0.000 (46.24) 1.000 0,000 (87.292) 1.000 
Basal cost *POP 0.000 (56.632) 1.000 0,000 (106.911) 1.000 
Incremental cost *SUI 1040.90 (36.273) 
0.000 1078.49 
(66.787) 
0.000 
Incremental cost *MUI 1266.69 (65.393) 
0.000 1486.10 
(123.45) 
0.000 
Incremental cost *POP 1626.22 (80.09) 
0.000 1626.22 
(151.195) 
0.000 
Equation 2 
Basal effectiveness *SUI 0.752 (0.025) 0.000 0.054 (0.005) 0.000 
Basal effectiveness *MUI 0.731 (0.046) 0.000 0.067 (0.010) 0.000 
Basal effectiveness *POP 0.82 (0.057) 0.000 0.072 (0.012) 0.000 
Incremental 
effectiveness *SUI 0.049 (0.036) 0.178 0.127 (0.007) 
0.000 
Incremental 
effectiveness *MUI 0.011 (0.066) 0.864 0.098 (0.014) 
0.000 
Incremental 
effectiveness *POP 0.021 (0.081) 0.792 0.079 (0.017) 
0.000 
(*) SUI: stress urinary incontinence; MUI: mixed urinary incontinence; POP: urinary incontinence 
associated with pelvic organ pr 
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The confidence ellipses of Model 1.1 at 50%, 75% and 95% relative to the effectiveness 
with the EQ-index (Figure 2) indicate that the increment in costs does not indicate a 
proportional increase in the effectiveness, and the baseline effectiveness does not determine the 
incremental costs. 
Figure 2  
(Model 1.1) EQ-index confidence ellipses  
(E=effectiveness; C= cost; b= basal) 
 
 
 
For Model 1.2, the confidence ellipses (Figure 3) demonstrate that the increase in cost 
has a tendency towards a lower increment in effectiveness and a high basal effectiveness implies 
higher cost increments. 
1040
1080
1120
1160
1200
1240
1280
C
 
in
cr
em
en
ta
l
.70
.72
.74
.76
.78
.80
.82
E 
b
-.04
.00
.04
.08
.12
-80 -40 0 40 80
E 
in
c
re
m
e
n
ta
l
C b
1050 1100 1150 1200 1250 1300
C incremental
.70 .72 .74 .76 .78 .80 .82
E b
13 
 
Figure 3  
(Model 1.2) ICIQ-SF confidence ellipses 
(E=effectiveness; C= cost; b= basal) 
 
 
 
The CEAC for the EQ-index establishes that for a 50% probability of obtaining an 
Incremental Net Benefit (INB), the increment in the willingness to pay is 30,674 €/QALY 
(Figure 4) with 20,961 €/QALY for SUI, 112,216 €/QALY for MUI and 76,116 €/QALY for 
that associated with POP (Figure 5). 
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Figure 4 
Cost-effectiveness acceptability curve with EQ-5D 
 
 
Figure 5  
Cost-effectiveness acceptability curve with the EQ-5D by the type of UI. 
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The CEAC with ICIQ-SF indicates a 50% probability of INB of 10,659 €/incremental 
area of modified ICIQ-SF (Figure 6), with 8,460, 15,145 and 20,394 €/incremental area of 
modified ICIQ-SF for SUI, MUI and POP, respectively (Figure 7). 
Figure 6 
Cost-effectiveness acceptability curve with the ICIQ-SF 
 
Figure 7 
Cost effectiveness acceptability curve with the ICIQ-SF by the type of UI 
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The analysis allows detecting how SUI obtains probabilities at 50% of INB more cost-
effective in each of the models. 
 
COMMENTS  
The economic literature concerning the surgical treatment of UI uses different HRQL 
questionnaires for the calculation of QALY. Manca et al (1) and Dumville et al (3) used the 
generic questionnaire, EQ-5D. The first obtained increments of QALY at 6 months of 0.397 and 
0.387 with TVT and laparoscopic colposuspension, respectively. The second obtained QALY 
for open colposuspension and laparoscopic colposuspension of 0.421 and 0.416 at 6 months, 
respectively, and of 0.818 and 0.833 at 1 year, respectively. Performing a literature review to 
compare TVT with open colposuspension, Wu et al (5)  applied utility values published by other 
authors (27, 28) based on HRQL in chronic diseases or in women who underwent surgery for 
urinary incontinence using the Health Utilities Index (HUI). The HUI for urinary incontinence 
was 0.73 and 0.95 after treatment, a value that was significantly different from the one attained 
by the EQ-index. 
Recently, Lier et al (29) compared TVT with TOT using an HRQL with 15 dimensions 
(15-D)(30). The index values were 0.878 and 0.864 at baseline and 0.899 and 0.897 at 1 year for 
TOT and TVT, respectively. At 6 weeks, the index values were higher (0.917 and 0.902), 
indicating an early “euphoria” caused by of the remission of UI and the negative effects that 
time can have. 
There are several HRQL generic questionnaires that can be used to evaluate 
effectiveness. However, for orthodoxy and to establish comparisons with other health 
programmes, the reference is EQ-5D, which is used most often to determine the QALY(31). 
It is important to note the need to use intermediate results of the effectiveness measures, 
as we have done herein at 1 month after the surgery, to adjust the calculation of the QALY 
according to the area under the curve (13). The exclusive application of annual measures can 
lead to an under- or overestimation of the impacts on the quality of life (32). Intermediate 
results become essential for the measurement of effectiveness in pathologies such as UI, for 
which there are short-term results of treatment; in these cases the HRQL questionnaires would 
better reflect the changes. 
For the long-term calculation of effectiveness and costs, we applied an annual discount 
rate of 3%, the same as that published by Wu et al (5). This rate was also proposed by the US 
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Panel on Cost-Effectiveness (26) and was assumed by the Spanish Health Economics 
Association as the rate for the reference case (25). 
The ICER results in the literature indicated better cost-utility ratios for laparoscopic 
surgery techniques or slings compared with traditional surgery and for TOT compared with 
TVT. In the review by Cody et al(2), at 5 years, TVT exhibited a lower cost (267£ less) than 
traditional surgical techniques with an equal or higher QALY (+ 0.00048). The probability that 
TVT was cost-effective was 95% for 20,000 £/QALY. Manca et al(1) demonstrated a lower cost 
(243£ less) and a higher utility (0.01 QALY) for TVT compared with colposuspension. At 6 
months, the probability that TVT was more cost-effective was 94.6% for an ICER of 30,000 
£/QALY. However, the review by Kilonzo et al (33) revealed that 5 years must elapse for the 
TVT results to be cost-effective compared with colposuspension. 
We have not found any CEA in the literature the calculates an ICER specific for UI. 
This study could serve as the first such reference: 106.52€ per unit measured with ICIQ-SF at 
one year. In their study of CEA, Valpas et al (6) did not calculate an ICER; their results were 
evident: TVT is less expensive (- 1,180.1€) and more effective (1.9 points with the specific 
UISS) than colposuspension. 
Although the threshold of the ICER has been adopted as 30,000 €/QALY, this aspect is 
not free from discussion. This reference was suggested for Spain by Sacristán et al (14) and 
endorsed by Ortún in 2004 (34). In 2010, NICE established (35) that a cost per treatment higher 
than 20,000-30,000 £/QALY cannot be considered cost-effective. A practical analysis for the 
monetary estimation of QALY was published by Baker et al (36), who proposed the 
approximation of the observations of NICE and public opinion surveys regarding the 
willingness to pay. In the Spanish population, Pinto et al (37) tried to estimate the monetary 
value per QALY and concluded that obtaining a unique value is difficult. 
The generalisation of our results might not be possible because they have been obtained 
in a specific population and at a public medical centre. The results of surgery and the re-
interventions either for the extrusion or persistence of incontinence reflect the experiences of 
this centre. Additionally, the cost figures cannot be considered typical because of standardised 
practices, such as local anaesthesia or outpatient surgery, the latter being crucial for Manca et al 
(1) to establish the superiority of TVT in terms of cost-effectiveness. Moreover, the variations 
in the costs of personnel and anti-incontinence devices can vary between countries and between 
hospitals. 
There are some limitations to this study: the number of patients, the different types of 
UI and the different surgical techniques employed. The follow-up collected herein was only 
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conducted at 1 year, the results at 5 years were based on data from our experience and from 
other series and should be considered only as an approximation. However, we used utility 
indices measured from validated questionnaires in specific patients with a specific pathology 
and after a surgical procedure, with individualised costs per patient not based only on the 
average, thereby offering additional opportunities to reduce costs (38). However, as we used 
ICIQ-SF, the study can be used as a reference to compare the results of the cost-effectiveness of 
treatments for UI and in both sexes with specific questionnaires without needing to run complex 
studies of cost-utility with the determination of QALY. 
Eventually, the assumption made that the untreated patients maintain the same EQ-
index during the period considered instead of the experiencing a reduction in their quality of 
life, a more likely outcome, implies that the estimates of QALYs gained represent a lower 
bound. Moreover, taking into account our assumption of an initial costs of 0 €, any other 
consideration should lead to a lower ICER value. 
CONCLUSIONS 
We can affirm that the surgical treatment of female urinary incontinence with slings is 
cost-effective compared with abstention in our public health environment. At 1 year, surgery for 
SUI is more cost-effective than that for the other two types of incontinence, MUI and that 
associated with POP. 
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